Keywords: cytokine; COVID-19; clinical value; course of
disease;
Q: What’s already known about this topic?
A: Symptoms of COVID-19 patients, infection pathways of
SARS-CoV-2, and the COVID-19 patients have higher cytokines.
Q: What does this article add?
A: What kinds of cytokines of COVID-19 patients were increased,
whether they serve as diagnostic biomarkers of COVID-19 and offer
prognostic insight upon initial presentation to help guide treatment,
their relationship with age, gender,antibody concentration and course
of disease were also discussed.
Coronavirus disease 19 (COVID-19) was first discovered in Wuhan, Hubei
in December 2019 [1], then the epidemic spread
throughout China and other countries and regions abroad[2]. The virus has high infectivity and caused
serious damage to the global economy and the health of people all over
the world. The main methods for diagnosing novel coronavirus
(SARS-CoV-2) were nucleic acid detection and serological antibody
detection [3]. According to diagnosis and
treatment plan of COVID-19 (trial version 7) issued by the office of the
Chinese health and Health Commission and the office of the State
Administration of traditional Chinese medicine, inflammatory factors are
often increased in severe and critical patients[4]. The immune cells can secrete cytokines (CKs)
such as interleukin (IL), colony-stimulating factor (CSF), chemokine,
interferon (IFN), tumor necrosis factor (TNF) and growth factor (GF)
which can induce the activation, proliferation or migration of target
cells by binding to specific receptors on a variety of cells when the
body was immune to exogenous substances [5]. Our
study aims to detect the expression level of IL-10, IL-1β, IL-6,
monocyte chemoattractant protein-1 (MCP-1), TNF-α, interferon-inducible
protein -10 (IP-10) and IL-4 in the blood of in COVID-19 patients, other
diseases patients and healthy people, and discuss its diagnostic value
for diagnosis of COVID-19.
Materials and methods